SUNNYVALE, Calif., July 12, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for human disorders including Parkinson's disease and Traumatic Brain Injuries (TBI) centered on its proprietary anti-apoptotic therapeutic protein known as MANF, today announced that its President & CEO Gerald E. Commissiong will be presenting a corporate overview today, July 12th, 2012, to be broadcast live from OneMedForum 2012 Conference at 11:20am ET from the Metropolitan Club in New York City. To watch the webcast live, click on the link http://www.onemedplace.com/forum/webcast/ .
EVENT INFORMATION AT A GLANCE:
WHO: Gerald Commissiong, President and Chief Executive Officer
WHEN: July 12th, 2012 at 11:20am ET
WHERE: Metropolitan Club, New York City
About OneMedForum 2012
OneMedPlace Trans-Atlantic Conference is the definitive conference in North America for fast-growing and emerging healthcare and life sciences companies. The 3rd annual New York Conference will bring together these emerging companies with venture and strategic investors within a unique networking and educational forum. Thought leaders in the disruptive technologies space across a variety of healthcare divisions will present both strategic insights and investment ideas to an international audience of the industry's movers and shakers.
This year, OneMedPlace explores the exciting investment opportunities, challenges and forward looking strategies in four sectors on the cusp of significant change:
- Health Information
- Regenerative Medicine.
The OneMedForum NY was recognized by Mayor Michael R. Bloomberg as an important event supporting innovation in the healthcare and life science industries "giving them the support, guidance and information they need to raise capital and develop innovative new ideas." Bloomberg proclaimed June 29th - 30th in the city of New York as "OneMedForum Day."
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and TBI. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408.737.2734 x 102
|SOURCE Amarantus BioSciences, Inc.|
Copyright©2012 PR Newswire.
All rights reserved